The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
FRI04 - Product Theater 1 | Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion | Focus on Adults with Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea (non-CE) Presentation by Incyte
Review the clinical and pathophysiological features of polycythemia vera (PV)
Describe the characteristics of advanced PV
Discuss the pivotal RESPONSE trial of Jakafi® (ruxolitinib) in patients with PV who are resistant to intolerant to hydroxyurea, including primary outcomes, safety, and long-term data
Discuss the RESPONSE-2 trial of Jakafi® (ruxolitinib) in patients with PV without splenomegaly, including primary outcomes and safety data
Apply clinical concepts to 3 real-world case studies of patients with characteristics of advanced PV
